Klivira
Request demo

Navigating Humana Tecentriq Prior Authorization

Efficiently manage **Humana Tecentriq prior authorization** to ensure timely access for patients requiring this critical oncology immunotherapy.

For revenue cycle directors and prior authorization teams, navigating specialty drug approvals like Tecentriq (atezolizumab) with a major payer like Humana presents unique challenges. Understanding specific submission channels, policy criteria, and operational nuances is key to minimizing delays and reducing administrative burden.

Understanding Tecentriq's Place in Humana's UM Landscape

Tecentriq (atezolizumab) is a PD-L1 inhibitor immunotherapy indicated for various advanced or metastatic cancers, including non-small cell lung cancer, hepatocellular carcinoma, and urothelial carcinoma. As a high-cost, specialty injectable, it is a frequent target for prior authorization across commercial, Medicare Advantage, and Medicaid managed care plans, necessitating detailed clinical documentation to support medical necessity.

Humana Prior Authorization Channels for Tecentriq

For medical-benefit specialty drugs like Tecentriq, Humana primarily routes prior authorization requests through its medical PA channel. Providers can initiate and manage these requests via the Availity Essentials provider portal, which serves as a central hub for eligibility lookup, PA initiation, and document upload. Additionally, X12 278 transactions are accepted through clearinghouses for impacted procedures, providing an electronic submission pathway. While CenterWell Specialty Pharmacy handles certain specialty injectables on the pharmacy benefit, Tecentriq typically falls under the medical benefit for infusion administration.

Key Policy Considerations for Humana Tecentriq Coverage

Humana publishes its medical policy and coverage determination documents on its provider site, which should be referenced by specific policy or coverage-determination number. For its significant Medicare Advantage enrollment, Humana's coverage policies for Tecentriq must align with applicable CMS National Coverage Determinations (NCDs) and Local Coverage Determinations (LCDs), and cannot impose criteria more restrictive than Original Medicare. Medical necessity criteria often leverage nationally recognized guidelines, such as the NCCN Compendium for oncology, or internal Humana-developed criteria.

Anticipating Humana Tecentriq Prior Authorization Denials

Common denial reasons for Tecentriq prior authorizations from Humana often include insufficient documentation to support medical necessity, non-adherence to specific NCCN or Humana policy criteria, or non-coverage under applicable NCDs/LCDs for Medicare Advantage plans. Denials may also occur due to site-of-service mismatches or if required preceding therapies (step therapy) are not adequately documented, although specific formulary or step therapy requirements for Tecentriq should be verified against current plan documents.

Streamlining Appeals for Denied Tecentriq Authorizations

Should a Tecentriq prior authorization be denied, Humana outlines its appeal pathway in its provider manual and on its provider site. For Medicare Advantage lines, the appeal process follows the CMS-mandated 5-level appeal structure for organization determinations. Expedited appeals and peer-to-peer reviews are available options to address clinical concerns directly with Humana medical directors, potentially resolving issues before formal appeals are necessary.

Klivira's Role in Optimizing Humana Tecentriq PA

Klivira integrates directly with EMRs and connects to payer portals like Availity and X12 278 clearinghouses, automating the submission and tracking of Humana Tecentriq prior authorizations. Our platform helps ensure that all necessary clinical documentation is attached, reducing manual effort and improving first-pass approval rates. By centralizing workflows, Klivira assists organizations in meeting Humana's specific requirements and adhering to statutory turnaround times, including those mandated by CMS-0057-F for Medicare Advantage plans.

Frequently asked questions

What is the primary channel for submitting Tecentriq prior authorizations to Humana?

For medical-benefit Tecentriq, the primary channels for prior authorization submission to Humana are the Availity Essentials provider portal for direct online submission and management, and X12 278 transactions submitted via a clearinghouse. These channels facilitate the electronic exchange of PA requests and supporting clinical documentation.

Does Humana's Medicare Advantage Tecentriq policy differ from Original Medicare?

Humana's Medicare Advantage coverage policies for Tecentriq must align with applicable CMS National Coverage Determinations (NCDs) and Local Coverage Determinations (LCDs) for Original Medicare. By regulation, Medicare Advantage plans cannot impose prior authorization criteria that are more restrictive than Original Medicare's coverage rules for the same service.

What are common reasons for Humana to deny Tecentriq prior authorizations?

Common denial reasons for Tecentriq prior authorizations from Humana include insufficient clinical documentation to establish medical necessity, non-adherence to Humana's specific medical policy criteria or national guidelines like NCCN, and non-coverage under applicable NCDs/LCDs for Medicare Advantage. Denials can also occur due to site-of-service discrepancies or if required preceding therapies are not documented.

What are the typical turnaround times for Humana Tecentriq prior authorizations?

For Humana Medicare Advantage lines, statutory turnaround times for prior authorizations subject to CMS-0057-F are 7 calendar days for standard decisions and 72 hours for expedited decisions for impacted categories. For other organization determinations, standard pre-service decisions typically adhere to 14 calendar days, with expedited decisions within 72 hours.

How does Klivira support Tecentriq prior authorizations with Humana?

Klivira automates the submission and tracking of Tecentriq prior authorizations by integrating with EMRs and connecting to Humana's designated channels, including the Availity portal and X12 278. Our platform helps ensure complete documentation, tracks approval status, and facilitates timely communication, thereby streamlining the PA process and reducing administrative overhead.

Related coverage

Other tecentriq prior authorization by payer

Other tecentriq prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo